Table
of Contents
|
|
|
|
Preface |
xiii |
1 |
Disease Screening |
|
|
Abdominal Aortic Aneurysm |
2 |
|
Alcohol Abuse & Dependence |
3 |
|
Anemia |
4 |
|
Attention-Deficit/Hyperactivity Disorder |
5 |
|
Bacteriuria, Asymptomatic |
6 |
|
BacterialVaginosis |
7 |
|
Cancer |
|
|
Bladder |
8 |
|
Breast |
10 |
|
Cervical |
17 |
|
Colorectal |
22 |
|
Endometrial |
28 |
|
Gastric |
31 |
|
Liver |
32 |
|
Lung |
33 |
|
Oral |
35 |
|
Ovarian |
36 |
|
Pancreatic |
38 |
|
Prostate |
39 |
|
Skin |
42 |
|
Testicular |
43 |
|
Thyroid |
44 |
|
Carotid Artery Stenosis |
45 |
|
Celiac Disease |
46 |
|
Chlamydia |
47 |
|
Cholesterol & Lipid Disorders |
|
|
Children |
48 |
|
Adults |
49 |
|
Coronary Aitery
Disease |
51 |
|
Dementia |
54 |
|
Depression |
55 |
|
Developmental Dysplasia
of the Hip |
56 |
|
Diabetes Mellitus |
|
|
Gestational |
57 |
|
Type 2 |
58 |
|
Falls in the Elderly |
60 |
|
Family Violence and Abuse |
61 |
|
Gonorrhea |
62 |
|
Group B Streptococcal Disease |
63 |
|
Growth Abnormalities, Infant 64 |
|
|
Hearing Impairment |
65 |
|
Hemochromatosis |
66 |
|
Hemoglobinopathies |
67 |
|
Hepatitis B Virus Infection, Chronic |
68 |
|
Hepatitis C Virus Infection, Chronic |
69 |
|
Herpes Simplex Virus, Genital |
71 |
|
Human Immunodeficiency Virus |
72 |
|
Hypertension |
|
|
Children & Adolescents |
74 |
|
Adults |
75 |
|
Illicit Drug Use |
77 |
|
Kidney Disease, Chronic |
78 |
|
Lead Poisoning |
79 |
|
Motor Vehicle Safety |
81 |
|
Obesity |
|
|
Children |
82 |
|
Adults |
83 |
|
Osteoporosis |
84 |
|
Phenylkctonuria |
85 |
|
RH (D) Incompatibility |
86 |
|
Scoliosis |
87 |
|
Speech & Language Delay |
88 |
|
Syphilis |
89 |
|
Thyroid Disease |
90 |
|
Tobacco Use |
91 |
|
Tuberculosis, Latent |
93 |
|
Visual Impairment, Glaucoma, or Cataract |
94 |
2 |
DISEASE PREVENTION |
|
|
Primary Prevention of Cancer: NCI Evidence Summary |
96 |
|
Dental Caries |
104 |
|
Diabetes Mellitus,
Type 2 |
105 |
|
Domestic Violence |
106 |
|
Driving Risk |
107 |
|
Endocarditis |
108 |
|
Falls in the Elderly |
109 |
|
Gonorrhea, Ophthalmia
Neonalorum |
110 |
|
Group B Streptococcal Infection |
111 |
|
Human Immunodeficiency Virus, Opportunistic Infections |
112 |
|
Prevention Among HIV-Infected Adults |
113 |
|
Prevention Among HIV-Exposed and HIV-Infected Infants and
Children |
117 |
|
Hypertension |
121 |
|
Lifestyle Modifications |
122 |
|
Immunizations |
|
|
Adults |
123 |
|
Infants and Children |
124 |
|
Children and Adolescents |
125 |
|
Influenza |
|
|
Chemoprophylaxis |
126 |
|
Vaccination |
127 |
|
Motor Vehicle Injury, Prevention |
128 |
|
Myocardial Infarction |
129 |
|
Neural Tube Defects |
136 |
|
Obesity |
137 |
|
Osteoporotic Hip Fractures |
138 |
|
Pressure Ulcers |
139 |
|
Sexually Transmitted Infections |
141 |
|
Stroke |
142 |
|
Sudden Infant Death Syndrome |
147 |
|
Tobacco Use |
148 |
3 |
Disease Management |
|
|
Adrenal tncidcntalomas |
150 |
|
Alcohol Use Disorders |
151 |
|
Androgen Deficiency Syndrome |
152 |
|
Anxiety |
153 |
|
Asthma |
154 |
|
Atrial Fibrillation |
|
|
Management |
156 |
|
Benign Prostatic
Hyperplasia |
163 |
|
Bronchitis, Acute |
165 |
|
CA Survivorship |
|
|
Late Effects of C A Treatments |
166 |
|
Carotid Artery Stenosis |
171 |
|
Cataract in Adults |
|
|
Evaluation & Management |
172 |
|
Cerumen Impaction |
174 |
|
Cholesterol & Lipid Management |
|
|
Adults |
175 |
|
Children |
177 |
|
Constipation |
178 |
|
Contraceptive Use |
179 |
|
Chronic Obstructive Pulmonary Disease |
|
|
COPD Exacerbations |
182 |
|
Stable COPD |
183 |
|
Changes in Classifications |
184 |
|
Recommendations |
188 |
|
Additional Changes |
192 |
|
Coronary Artery Stenl
Therapy |
|
|
Use of Triple Anticoagulation Treatment |
193 |
|
Delirium |
195 |
|
Dementia |
196 |
|
Depression |
197 |
|
Diabetes Mellitus |
|
|
Type 1 |
198 |
|
Type 2 |
200 |
|
Erectile Dysfunction |
204 |
|
Glaucoma, Chronic Open Angle |
205 |
|
Headache |
206 |
|
Heart Failure |
214 |
|
Hepatitis B Virus |
215 |
|
Hepatitis C Virus |
216 |
|
Hoarseness |
217 |
|
Human Immunodeficiency Virus |
|
|
Adults and Children |
218 |
|
Pregnancy |
220 |
|
Anti retro viral Therapy |
222 |
|
Hypertension |
|
|
Initiating Treatment |
223 |
|
Lifestyle Modifications |
224 |
|
Recommended Medications for Compelling Indications |
225 |
|
Refractory Hypertension |
226 |
|
Influenza |
228 |
|
Kidney Disease |
|
|
Chronic |
229 |
|
Chronic-Mineral and Bone Disorders |
231 |
|
Kidney Stones |
232 |
|
Back Pain |
|
|
Low |
233 |
|
Evaluation and Management |
234 |
|
Metabolic Syndrome |
|
|
Identification & Management |
235 |
|
Methicillin-Resistant Staphylococcus Aureus |
236 |
|
Obesity Management |
238 |
|
Osteoporosis |
240 |
|
Glucocorticoid-lnduced |
242 |
|
Otitis Media, Acute |
244 |
|
Palliative & End-of-Life Care |
|
|
Pain Management |
246 |
|
Abnormal Pap Smear |
247 |
|
Perioperative Cardiovascular Evaluation |
248 |
|
Pneumonia, Community-Acquired |
|
|
Evaluation |
250 |
|
Suspected Pathogens 251 |
|
|
Pregnancy |
|
|
Routine Prenatal Care |
252 |
|
Perinatal & Postnatal Guidelines |
255 |
|
Psoriasis, Plai|uc-Type |
256 |
|
Rheumatoid Arthritis |
|
|
Biologic Disease-Modifying Antirheumatie Drugs |
257 |
|
Nonbiologic Disease-Modifying Antirheumatic
Drugs |
258 |
|
Noninfectious Rhinitis Management |
259 |
|
Sexually Transmitted Diseases |
260 |
|
Management of Thyroid Nodules |
267 |
|
Tobacco Cessation |
268 |
|
Acute Pharyngitis |
271 |
|
Urinary Incontinence |
|
Stress |
272 |
|
|
Men |
273 |
|
Women |
274 |
|
Urinary Tract Infections (UTIS) |
275 |
|
Lower Urinary Tract Symptoms (LUTS) |
277 |
|
Vertigo, Benign Paroxysmal Positional (BPPV) |
278 |
4 |
APPENDICES |
|
Appendix I |
Screening
Instruments |
|
|
Alcohol Abuse |
280 |
|
Depression |
283 |
|
Geriatric Depression Scale |
287 |
Appendix II |
Functional
Assessment Screening in the Elderly |
288 |
Appendix III |
Screening
and Prevention Guidelines in Perspective |
290 |
Appendix IV |
95th Perccntile of Blood Pressure |
|
|
Boys |
292 |
|
Girls |
293 |
Appendix V |
Body Mass
Index Conversion Table |
294 |
Appendix VI |
Cardiac
Risk-Fanningham Study Men |
295 |
|
Women |
297 |
Appendix VII |
Estimate of
10-Year Stroke Risk |
|
|
Men |
299 |
|
Women |
300 |
Appendix
VIII |
Immunizations
Schedules |
302 |
Appendix IX |
Professional
Societies and Governmental Agencies |
313 |
|
Index |
317 |
|
|
|